Developments Matinas gets FDA fast track, QIDP designations for MAT2203 The FDA granted fast track and qualified infectious disease product (QIDP) designations to Matinas BioPharma’s (NYSE AMER:MTNB) MAT2203 for the treatment of cryptococcal meningitis. MAT2203 is a lipid nano-crystal... July 25, 2019